0.45 kg rather than fat gain
The targeted delivery of dexamethasone to GLP1R-positive cells prevented typical dexamethasone offtarget effects on glucose metabolism, bone density, and the hypothalamus-pituitary-adrenal axis activity (164)
37 According to preliminary clinical trials, patients treated with exenatide improved by 2.7 points on the Movement Disorder Society-Unified Parkinsons Disease Rating Scale (MDS-UPDRS) after 12 months, compared to a decline of 2.2 points in control patients
Additionally, it led to a cell cycle arrest at the G0/G1 phase and a reduction in the number of cells in the S phase
Each KLOW vial is independently verified through third-party laboratory testing and ships with a Analytical Data Sheet (ADS)
However, a notable side effect was observed: MT-II-treated normal C57BL/6J mice exhibited significant weight loss, with their average weight decreasing from a baseline of 30.9 1.4 grams to 26.5 1.7 grams after the 14-day treatment course, a change not seen in vehicle-treated controls
